DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Global Learning Collaborative (GLC) designates this 15-minute enduring activity for a maximum of .25 AMA PRA Category 1 Credits™ and .25 nursing contact hours.
Dive into the intriguing realm of CAR T-cell therapy management, specifically pertaining to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Discover the latest clinical data and strategies to optimize patient outcomes.
Key Points:
- CAR T-cell therapy is a potentially transformative treatment for relapsed/refractory multiple myeloma.
- Current consensus grading systems exist for CRS and ICANS associated with CAR T-cell therapy.
- Understanding the signs and symptoms of CRS and ICANS is crucial for effective patient management.
Additional Points:
- Interdisciplinary team strategies are pivotal for successful management of CRS and ICANS in this patient population.
- This CME activity targets a wide array of healthcare professionals, including hematologists, oncologists, nurse practitioners, physician assistants, and nurses.
Conclusion:
- This educational activity serves as an essential guide for healthcare professionals seeking to deepen their understanding and effective management of CRS and ICANS in patients receiving CAR T-cell therapy.
Nursing Latest Posts
- Nearly 90,000 Bottles of Children’s Ibuprofen Recalled Over ‘Black Particles,’ FDA Says
- The Importance of the Childhood Immunization Schedule for Internal Medicine
- Mental Health Care for Transgender and Gender Diverse Youth
- Managing Cancer-Related Distress: Overview and Updates of the NCCN Guidelines
Did You Know?
According to research, CAR T-cell therapy has demonstrated impressive response rates of more than 80% in some studies with multiple myeloma patients who have exhausted other treatment options.
